|
Dr. Varney has spent over 15 years in the pharmaceutical industry, holding senior level positions at Sepracor, Inc., where he was Vice President and head of Discovery, and at Bionomics, Ltd., where he was Vice President of Drug Discovery. Prior to that, Dr. Varney held positions of increasing responsibilities over his six-year tenure at SIBIA Neuroscience, Inc., including his most recent position as Director of Neuropharmacology. Upon the acquisition of SIBIA by Merck, Inc in 1999, he was appointed a Director of Merck’s San Diego facility. Prior to SIBIA, he held research positions at Servier in France and Merck Sharp & Dohme in the U.K. Dr. Varney received his B.Sc. in Biochemistry with honors from Surrey University, U.K. and completed his Ph.D. and postdoctoral training at Oxford University, U.K.
Dr. Varney’s career has focused on drug discovery programs for treating schizophrenia, depression, cognitive disorders, anxiety, epilepsy and insomnia. He has been successful in developing drug candidates in several of these disease areas, and has filed numerous patent applications relating to new chemical entities and methods of use. Dr. Varney has published extensively in peer-reviewed journals, and is the Editor-in-Chief of the journal CNS & Neurological Disorders-Drug Targets. | 